Skip to main content
. 2021 Aug 31;13(9):1377. doi: 10.3390/pharmaceutics13091377

Table 3.

Encapsulation efficiency (E.E.) and drug loading (D.L.) of pCMV-βGal to the CS-based NCs (mean ± S.D.; n = 3).

Formulation E.E.
(%)
D.L.
(%)
pCMV-βGal-CS NCs 90.6 ± 0.9 36.2 ± 0.4
pCMV-βGal-HA/CS NCs 89.0 ± 4.8 35.6 ± 1.9